https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-72009-01-20 00:00:002019-02-15 08:49:30Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-13 / Cancer Immunol. Immunother. 2009 Aug;58(8):1257-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-13 / Cancer Immunol. Immunother. 2009 Aug;58(8):1257-642009-01-13 00:00:002019-02-15 08:44:20Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-12 / J. Clin. Oncol. 2009 Feb;27(6):945-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-12 / J. Clin. Oncol. 2009 Feb;27(6):945-522009-01-12 00:00:002019-02-15 08:49:55Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-09 / Immunol. Lett. 2009 Jan;122(1):58-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-09 / Immunol. Lett. 2009 Jan;122(1):58-672009-01-09 00:00:002019-02-15 08:44:28Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Klin Onkol 2009;22(2):67-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Klin Onkol 2009;22(2):67-722009-01-01 00:00:002019-02-15 08:50:58[The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Folia Biol. (Praha) 2009;55(4):119-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Folia Biol. (Praha) 2009;55(4):119-252009-01-01 00:00:002019-02-15 08:53:16Dendritic cell-based immunotherapy induces transient clinical response in advanced rat fibrosarcoma – comparison with preventive anti-tumour vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Cell. Immunol. 2009;257(1-2):23-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Cell. Immunol. 2009;257(1-2):23-312009-01-01 00:00:002019-02-15 08:50:13Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-662009-01-01 00:00:002021-11-15 17:02:36Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Hepatology 2009 Jan;49(1):124-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Hepatology 2009 Jan;49(1):124-322009-01-01 00:00:002020-01-08 10:10:21A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Drugs 2009;69(3):241-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Drugs 2009;69(3):241-92009-01-01 00:00:002019-02-15 08:46:48Tumour vaccine approaches for CNS malignancies: progress to date